Lv1
40 积分 2023-01-31 加入
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
2天前
已完结
Tumor Microenvironment-Responsive NanoShield for Precision Photodynamic and Photothermal Synergistic Cancer Therapy with Mitigated Skin Phototoxicity
1个月前
已完结
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
3个月前
已完结
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
4个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
5个月前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
5个月前
已完结
Unraveling the Natural History of Good’s Syndrome: A Progressive Adult Combined Immunodeficiency
5个月前
已完结
Current challenges in lung transplantation
5个月前
已完结
The clinical spectrum of thymoma-associated immunodeficiency: Good syndrome and beyond
5个月前
已完结
Unraveling the Natural History of Good’s Syndrome: A Progressive Adult Combined Immunodeficiency
5个月前
已完结
皖公网安备34019202002308
